Mark R. Hake

Mark R. Hake

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks.

Recent Articles

Stay Away From Sorrento Therapeutics Here

Sorrento Therapeutics looks overvalued here. Investors in SRNE stock can expect dilution from equity/debt raises, given the company's ongoing burn rate and deals.

Ford Is Still Undervalued, But its New CEO May Change This

Ford is still undervalued but its new CEO may change things. I think F stock is worth at least $8.40 if it resumes its 60-cent annual dividend next year.

Workhorse Stock Is on Track to Be an EV Winner

Workhorse stock is on track to be an EV winner. WKHS stock is worth at least 20% more or $23.71 per share, given expected sales, and its stake in Lordstown Motors.

4 SPAC Stocks With New Mergers and 2 Pre-Merger SPACs Worth a Look

These 4 SPAC stocks recently announced merger deals and most offer upside from 33% to over 100%. Plus, 2 pre-merger SPACs to consider.

Pfizer Stock Will Soar With Its First-Mover Vaccine Advantage

Pfizer will have first-mover advantage with its Covid-19 vaccine. But that is not the only reason to be bullish on PFE stock.